増加した心臓のカルディオトロフィン-1は,実験的な充血性心不全において
M Jougasaki1, I Tachibana, A Luchner
1Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN 55905, USA. jougasaki@mayo.edu
Circulation
|January 5, 2000
まとめ
Cardiotrophin-1 (CT-1) は,実験的な心不全において上昇調節され,左心室高縮と相関しています. これは,CT-1が充血性心不全 (CHF) 時の心臓の改造に重要な役割を果たしていることを示唆しています.
科学分野:
- 心血管生物学 心血管生物学
- 分子心臓病学 分子心臓病学
- 心臓のリモデリング
背景:
- カーディオトロフィン-1 (CT-1) は,強力な高縮性因子である.
- マウスの胚性幹細胞モデルを用いて発見された.
研究 の 目的:
- パイシング誘発性閉塞性心不全 (CHF) のCT-1発現を調査する.
- 冠動脈不全におけるCT-1と左心室縮の関連性を判定する.
主な方法:
- ペーシング誘発の実験的なCHFの犬のモデルを使用しました.
- CT-1発現を評価するために,Northern blot分析と免疫ヒスト化学を用いた.
- 左心室質量指数と相関する心室CT-1mRNA.
主要な成果:
- CT-1遺伝子発現は正常な心房と心室で検出されました.
- CT-1発現はCHFの心臓において有意に増加した.
- 静脈CT-1 mRNAは左心室質量と正の相関を示した.
- CT-1の免疫反応は,心筋梗塞の心臓筋細胞においてより強烈であった.
結論:
- 心房と心室の両方がCT-1を合成する.
- 心臓CT-1の生成は,実験的なCHFで増加しています.
- 静脈CT-1 mRNAは左心室高縮と相関しており,CHFの構造再構築における役割を果たしていることを示している.
関連する概念動画
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


